Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Chronic Weight Management: In June 2021, the FDA approved semaglutide (Wegovy) at a higher dose of 2.4 mg for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia
Slowing gastric emptying: This process helps slow the absorption of sugar and prevent rapid blood sugar increases after eating, stabilizing blood sugar control GLP-1 medications, such as Ozempic and Mounjaro, are effective in reducing HbA1c levels (a key measure of long-term blood sugar control) and help reduce the risk of complications associated with Type 2 diabetes
Renal impairment both can worsen dehydration-related acute kidney injury if GI side effects are severe
European Geriatric Medicine
Liu XY, Zhang N, Chen R, Zhao JG, Yu P
& Weindruch, R
